Alderline Group

Alderline Group is an investment firm.

Active

Updated: Mar 15, 2026 ·

About

Alderline Group is an investment firm established in 2022. The firm primarily focuses on investing in healthcare innovation and technology solutions. Its operational scope includes the venture capital and private equity sectors, targeting companies within biotechnology, life science, and pharmaceutical industries.

As an investment entity, Alderline Group participates in financing rounds for companies developing advanced solutions in these specialized fields. The firm's strategy centers on supporting the growth and development of innovative healthcare ventures.

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Feb 4, 2026	Third Arc Bio	$52.0M Series A	Andreessen Horowitz	AbbVie, Aberdeen Investments, Biotechnology Value Fund, Galapagos, Goldman Sachs Alternatives, Hillhouse Investment, Marshall Wace, Omega Funds, T. Rowe Price

Financial History

Total Raised

N/A

Valuation

N/A

Deep Dive

Alderline Group, founded in 2022, operates as an investment firm with a dedicated focus on the healthcare sector. The firm's investment mandate is specifically directed towards companies engaged in healthcare innovation and technology solutions. This includes a broad range of enterprises within the biotechnology, life science, and pharmaceutical industries, reflecting a strategic interest in advancements that can impact medical treatment and patient care.

The firm functions within the venture capital and private equity landscape, indicating its involvement in both early-stage and more mature companies. Its role typically involves providing capital to support the development, expansion, and commercialization of new technologies and therapies. This financial backing is crucial for companies operating in research-intensive and capital-intensive sectors like biotechnology and pharmaceuticals.

Alderline Group has been noted for its participation in significant financing rounds. For instance, the firm was among the investors in Parabilis Medicines' oversubscribed $305 million financing. This involvement underscores Alderline Group's commitment to supporting companies that are advancing clinical development and pioneering new pipelines in areas such as oncology.

By concentrating its investment efforts on healthcare innovation, Alderline Group aims to contribute to the growth of companies that are developing novel solutions. Its investment activities are designed to foster progress in areas that can lead to new medical breakthroughs and improved healthcare outcomes.

Sources

Frequently Asked Questions

What specific sectors does Alderline Group target for investment?

Alderline Group primarily targets healthcare innovation and technology solutions, with a particular focus on companies within the biotechnology, life science, and pharmaceutical industries.

How does Alderline Group participate in company financing?

Alderline Group participates as an investor in financing rounds for companies, such as its involvement in Parabilis Medicines' oversubscribed $305 million financing to support clinical development.

What type of investment firm is Alderline Group?

Alderline Group operates as an investment firm within the Venture Capital and Private Equity Principals industry.